WO2009038659A2 - Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy - Google Patents
Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy Download PDFInfo
- Publication number
- WO2009038659A2 WO2009038659A2 PCT/US2008/010608 US2008010608W WO2009038659A2 WO 2009038659 A2 WO2009038659 A2 WO 2009038659A2 US 2008010608 W US2008010608 W US 2008010608W WO 2009038659 A2 WO2009038659 A2 WO 2009038659A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- photosensitizer
- nanoparticles
- nanoparticle
- group
- groups
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 156
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 135
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title abstract description 22
- 238000002428 photodynamic therapy Methods 0.000 title description 23
- 238000012377 drug delivery Methods 0.000 title description 3
- 239000012216 imaging agent Substances 0.000 claims abstract description 47
- -1 benzochlorins Chemical class 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 150000004036 bacteriochlorins Chemical class 0.000 claims abstract description 8
- 150000004035 chlorins Chemical class 0.000 claims abstract description 8
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000004032 porphyrins Chemical class 0.000 claims abstract description 7
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 5
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 5
- 239000003446 ligand Substances 0.000 claims abstract description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 27
- 229920000053 polysorbate 80 Polymers 0.000 claims description 27
- 239000011159 matrix material Substances 0.000 claims description 24
- FWDBOZPQNFPOLF-UHFFFAOYSA-N ethenyl(triethoxy)silane Chemical compound CCO[Si](OCC)(OCC)C=C FWDBOZPQNFPOLF-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 230000008685 targeting Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000000975 dye Substances 0.000 claims description 12
- 238000003384 imaging method Methods 0.000 claims description 12
- 229910000077 silane Inorganic materials 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 238000012632 fluorescent imaging Methods 0.000 claims description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 150000004756 silanes Chemical class 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 229910052733 gallium Inorganic materials 0.000 claims description 6
- 229910052738 indium Inorganic materials 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 238000006557 surface reaction Methods 0.000 claims description 5
- ZNOCGWVLWPVKAO-UHFFFAOYSA-N trimethoxy(phenyl)silane Chemical compound CO[Si](OC)(OC)C1=CC=CC=C1 ZNOCGWVLWPVKAO-UHFFFAOYSA-N 0.000 claims description 5
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 150000007514 bases Chemical class 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 claims description 3
- UUEWCQRISZBELL-UHFFFAOYSA-N 3-trimethoxysilylpropane-1-thiol Chemical compound CO[Si](OC)(OC)CCCS UUEWCQRISZBELL-UHFFFAOYSA-N 0.000 claims description 3
- XDLMVUHYZWKMMD-UHFFFAOYSA-N 3-trimethoxysilylpropyl 2-methylprop-2-enoate Chemical compound CO[Si](OC)(OC)CCCOC(=O)C(C)=C XDLMVUHYZWKMMD-UHFFFAOYSA-N 0.000 claims description 3
- 238000012879 PET imaging Methods 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- NKSJNEHGWDZZQF-UHFFFAOYSA-N ethenyl(trimethoxy)silane Chemical group CO[Si](OC)(OC)C=C NKSJNEHGWDZZQF-UHFFFAOYSA-N 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 claims description 3
- AHYFYQKMYMKPKD-UHFFFAOYSA-N 3-ethoxysilylpropan-1-amine Chemical compound CCO[SiH2]CCCN AHYFYQKMYMKPKD-UHFFFAOYSA-N 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940123038 Integrin antagonist Drugs 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 230000002165 photosensitisation Effects 0.000 claims description 2
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 238000012831 peritoneal equilibrium test Methods 0.000 claims 1
- 238000012636 positron electron tomography Methods 0.000 claims 1
- 238000012877 positron emission topography Methods 0.000 claims 1
- 238000000799 fluorescence microscopy Methods 0.000 abstract description 6
- 230000002028 premature Effects 0.000 abstract description 6
- 239000000377 silicon dioxide Substances 0.000 abstract description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 239000000693 micelle Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- CZDVFYPMFNMMCR-UHFFFAOYSA-N 3-[1-(2-carboxyethyl)anthracen-2-yl]propanoic acid Chemical compound C1=CC=CC2=CC3=C(CCC(O)=O)C(CCC(=O)O)=CC=C3C=C21 CZDVFYPMFNMMCR-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000002600 positron emission tomography Methods 0.000 description 11
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000004061 bleaching Methods 0.000 description 7
- 239000012465 retentate Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 230000004700 cellular uptake Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 229910001882 dioxygen Inorganic materials 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229930187593 rose bengal Natural products 0.000 description 4
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 4
- 229940081623 rose bengal Drugs 0.000 description 4
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- PHRHANASDXMZLU-UHFFFAOYSA-N 3-[10-(2-carboxyethyl)anthracen-9-yl]propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=C(C=CC=C3)C3=C(CCC(O)=O)C2=C1 PHRHANASDXMZLU-UHFFFAOYSA-N 0.000 description 2
- TVTRDGVFIXILMY-UHFFFAOYSA-N 4-triethoxysilylaniline Chemical compound CCO[Si](OCC)(OCC)C1=CC=C(N)C=C1 TVTRDGVFIXILMY-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000004735 phosphorescence spectroscopy Methods 0.000 description 2
- 230000002186 photoactivation Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PUUBADHCONCMPA-USOGPTGWSA-N 3-[(21S,22S)-11-ethyl-16-(1-hexoxyethyl)-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid Chemical compound CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6[C@H]([C@@H](C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C PUUBADHCONCMPA-USOGPTGWSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- JUDGRMABQJKRPW-XIADSQHASA-N CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C Chemical compound CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C JUDGRMABQJKRPW-XIADSQHASA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 125000005372 silanol group Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to the field of nanoparticle mediated drug delivery in photodynamic therapy.
- Photodynamic therapy a light-activated treatment for cancer and other diseases
- PS photosensitizers
- the therapeutic effect is activated by the photoexcitation of the localized photosensitizers and the subsequent generation of cytotoxic species, such as singlet oxygen (1O2), free radicals or peroxides, which lead to selective and irreversible destruction of the diseased tissues without damaging adjacent healthy ones.
- Photodynamic therapy is based on the concept that certain therapeutic molecules called photosensitizers (photosensitizer) can be preferentially localized in malignant tissues, and when these photosensitizers are activated with appropriate wavelength of light, they pass on their excess energy to surrounding molecular oxygen resulting in the generation of reactive oxygen species (ROS), such as free radicals and singlet oxygen ( 1 O 2 ), which are toxic to cells and tissues.
- ROS reactive oxygen species
- PDT is a non-invasive treatment and used for several types of cancers, and its advantage lies in the inherent dual selectivity.
- selectivity is achieved by a preferential localization of the photosensitizer in target tissue (e.g. cancer)
- second, the photoirradiation and subsequent photodynamic action can be limited to a specific area. Since the photosensitizer is non-toxic without light exposure, only the irradiated areas will be affected, even if the photosensitizer does infiltrate normal tissues.
- colloidal carriers for photosensitizers such as oil- dispersions, liposomes, low-density lipoproteins, polymeric micelles, and recently ceramic nanoparticles are examples of delivery shuttles for photosensitizer molecules some of which may offer benefits from rendering aqueous stability and appropriate size for passive targeting to tumor tissues by the "enhanced permeability and retention" (EPR) effect, offering a possibility of bioconjugation approaches to enhance bioavailability as well as tumor targeting and offering a possibility of actively targeting tumor tissues by appropriate surface functionalization.
- EPR enhanced permeability and retention
- nanoparticles containing covalently linked photosensitizer molecules are provided to overcome the drawback of their premature release and thus enhance the outcome of PDT.
- silica-based nanoparticles are provided containing at least one covalently linked photosensitizer.
- the photosensitizer is preferably a tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides, and phthalocyanines, naphthanocyanines with and without fused ring systems and derivatives of all the above.
- the nanoparticle may also include covalently linked imaging agents, e.g. radionuclides, magnetic resonance (MR) and fluorescence imaging agents.
- MR magnetic resonance
- the imaging agents and photosensitizers may be at a periphery (surface) of the nanoparticles to increase efficiency.
- Target-specific nanoparticles may be provided by incorporating biotargeting molecules such as specific antibodies at the surface that react with particular ligands to obtain target specificity. Diagnostic agents may be present in the antibody in addition to imaging agents and tumor specific photosensitizers as previously and subsequently discussed.
- the nanoparticle of the invention has the structural formula:
- the ring represents a silicone polymer matrix
- R 4 is (Ri) n -R 2 -(Rs) n
- Ri is a labeled photosensitizer (IP) or unlabeled photosensitizer (P), cyanine dye, SPECT imaging agent, PET imaging agent, MR imaging agent or fluorescent imaging agent at least partially available at a surface of the silicone polymer matrix
- R 2 is -O-, -COO-, -NR 5 or -NH- connected to the silicone polymer matrix directly or through an intermediate group, n is 0 or 1; provided that at least one n is 1 and R3 is cyanine dye, SPECT, PET, MR or fluorescent imaging agent, linked targeting agent RGD, F3 peptide, carbohydrate or folic acid or labeled photosensitizer (IP) or unlabeled photosensitizer (P) embedded in the silicone polymer matrix
- R5 is lower alkyl of from 1 to 5 carbon atoms where a plurality of
- Figure IA shows graphic results of spin-filtration of various formulations of
- the graph shows the relative optical densities (read at 663 nm, the long- wavelength absorbance peak for IP) of the 'filtrate' and 'retentate' fractions, as well as the non-filtered 'original' samples, for cell lines NY-362 through NY-365.
- the non-silylated photosensitizer 3-iodobenzyl-pyro, or EP is used as the control, both dissolved in Tween-80 micelles as well as encaphotosensitizerulated in ORMOSIL nanoparticles.
- Figure IB shows a TEM image of NY-363.
- FIG. 1C shows a scheme 1 for synthesis of the precursor 3-iodobenzylpyro- silane (EPS) shown as compound II.
- EPS 3-iodobenzylpyro- silane
- IP compound I
- Figure 2 shows emission of EP upon UV irradiation following TLC of EP- conjugated (lane 1) and encapsulated (lane 2) ORMOSlL nanoparticles.
- Lane 3 shows the same for EP/1 % Tween-80.
- Figure 3A shows absorption spectra of the "micelle free" nanoparticle samples (retentate collected after spin-filtration and resuspended), as well as non-filtered micellar suspensions of EP/Tween-80 and NY-362 (100% of EPS, no VTES). Fluorescence was obtained on exciting the molecule at 514 nm.
- Figure 3B shows fluorescence spectra of the "micelle free” nanoparticle samples (retentate collected after spin-filtration and resuspended), as well as non-filtered micellar suspensions of EP/Tween-80 and NY-362 (100% of EPS, no VTES). Fluorescence was obtained on exciting the molecule at 514 nm.
- Figure 4A shows results on singlet oxygen production by "micelle-free" suspensions of nanoparticles which were obtained by singlet oxygen phosphorescence spectroscopy, showing remarkable similarity to those obtained following the same trend: EP/Tween-80 micellar suspension demonstrated higher 1 O 2 generation than NY-363, NY-364, NY-365; whereas, intensitiy for NY-362 is lower.
- FIG 4B shows results on singlet oxygen production by "micelle-free" suspensions of nanoparticles, obtained using an ADPA (anthracenedipropionic acid) bleaching method.
- ADPA anthracenedipropionic acid
- Non-spin-filtered micellar suspensions of EP/Tween-80 and NY-362 (100% of Iphotosensitizer, no VTES) were used as controls.
- Rose Bengal (RB) in methanol was used as a reference standard for the 1 O 2 phosphorescence measurements. This means that singlet oxygen generated within nanoparticles is mostly deactivated outside nanoparticles, causing bleaching of ADPA. Irradiation with 514 nm, applied laser power was 5 times higher for the bleaching experiment than for spectra acquisition.
- Figure 5 shows decays of the emission from Iphotosensitizer/VTES nanoparticle and IP Tween-80 suspensions at 1270 nm.
- Figure 6 shows combined comparative photomicrographs Figure 6 of Colon-
- Figure 7 shows a nonoparticle 10 having R4 groups where the ring represents a silicone polymer matrix.
- R 4 is (Rt) n -R 2 -(Rs) n .
- Ri is a labeled photosensitizer (IP) or unlabeled photosensitizer (P), cyanine dye, SPECT imaging agent, PET imaging agent, MR imaging agent or fluorescent imaging agent at least partially available at a surface of the silicone polymer matrix.
- R 2 is -O-, -COO-, -NR5 or -NH- connected to the silicone polymer matrix directly or through an intermediate group, n is 0 or 1; provided that at least one n is 1.
- R3 is cyanine dye, SPECT, PET, MR or fluorescent imaging agent, linked targeting agent RGD, F3 peptide, carbohydrate or folic acid or labeled photosensitizer (IP) or unlabeled photosensitizer (P) embedded in the silicone polymer matrix.
- R 5 is lower alkyl of from 1 to 5 carbon atoms where a plurality of Ri groups, R 2 groups or mixtures thereof are photosensitizer and/or labeled photosensitizer.
- IP I 124 -labeled photosensitizer
- targetingents e.g. RGD, F3 peptides, carbohydrates and folic acid.
- nanoparticles containing covalently linked photosensitizer molecules are provided to overcome the drawback of their premature release and thus enhance the outcome of PDT.
- silica-based nanoparticles are provided containing at least one covalently linked photosensitizer.
- the photosensitizer is preferably a tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides.
- Specific ezamples of such photosensitizers may, for example be found in U.S.
- the nanoparticle may also include covalently linked imaging agents, e.g. radionuclides, magnetic resonance (MR) and fluorescence imaging agents.
- the imaging agents and photosensitizers may be at a periphery (surface) of the nanoparticles to increase efficiency.
- Target-specific nanoparticles may be provided by incorporating biotargeting molecules such as specific antibodies at the surface that react with particular ligands to obtain target specificity. Diagnostic agents may be present in the antibody in addition to imaging agents and tumor specific photosensitizers as previously and subsequently discussed.
- the nanoparticle of the invention has the structural formula:
- R 4 is (Ri) n -R 2 -(Rs) n where Ri is a labeled photosensitizer (IP) or unlabeled photosensitizer (P), cyanine dye, SPECT (single proton emission computed tomography) imaging agent, PET (positron emission tomography) imaging agent, MR imaging agent or fluorescent imaging agent at least partially available at a surface of the silicone polymer matrix.
- IP labeled photosensitizer
- P unlabeled photosensitizer
- cyanine dye cyanine dye
- SPECT single proton emission computed tomography
- PET positron emission tomography
- MR imaging agent positron emission tomography
- At least one Ri or R 3 group may be a tetrapyrollic photosensitizer, e.g. porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrins, pheophorbides including pyropheophorbides, and derivatives thereof.
- R 2 is -O-, -COO-, -NR5 or -NH- connected to the silicone polymer matrix directly or through an intermediate group.
- the intermediate group may, for example, be subtituted or unsubstituted alkylene or phenylene.
- the alkylene or phenylene may be substituted with at least one hydroxy, carboxy, amino, sulfo, alkylester, alkylether, heterocyclo, or halo group.
- n is 0 or 1 ; provided that at least one n is 1.
- R3 is cyanine dye, SPECT, PET, MR or fluorescent imaging agent, linked targeting agent RGD, F3 peptide, carbohydrate or folic acid or labeled photosensitizer (IP) or unlabeled photosensitizer (P) embedded in the silicone polymer matrix.
- RGD is a peptide that contains the Arg-Gly-Asp attachment site that recognizes v3 and v5 integrin receptors that play a role in angiogenesis, vascular intima thickening and proliferation of malignant tumors.
- R 5 is lower alkyl of from 1 to 5 carbon atoms.
- a plurality of Ri groups, R3 groups or mixtures thereof are photosensitizer and/or labeled photosensitizer.
- the Ri or R 3 group may be phthalocyanine, naphthanocyanine and derivatives thereof and may also be a radionuclide or MR or fluorescencent imaging agent.
- a plurality of Ri groups are preferably photosensitizers located at peripheral positions on the nanoparticle and a plurality of R 3 groups are imaging agents located at peripheral positions on the nanoparticle.
- the nanoparticle are desirably provided with biotargeting molecules following suitable surface functionalization to obtain target-specific nanoparticles.
- biotargeting molecules examples include antibodys and the suitable surface functionalization for the antibody is a ligand, e.g. RGD and F3 peptide..
- the nanoparticle may further include at least one diagnostic agent.
- Photosensitiers as used herein means any material that can enter or attach to a cell or portion thereof and be activated by eletromagnetic radiation, usually light, to destroy the cell or significantly alter its activity.
- nanoparticles made of an organically modified silica refers to nanoparticles made from silica that has been organically modified to self organize into polysicone nanoparticles upon precipitation from solution.
- Preferred organically modified silica nanoparticles are ORMOSIL nano particles usually made by inclusion of a vinyltriethoxysilane in a sufactant solution followed by precipitation with ammonia or other amine, e.g. 3 aminopropyltriethoxy silane. In the first case the nanoparticle has surface -OH groups and in the second case has surface amino groups.
- the silane (silicone) matrix is formed by self reaction of hydroxy silanes by dehydration to form a polymeric silicone matrix of silcon atoms interconnected by oxygen atoms.
- the starting silanes have the formula R 4 Si where R is independently at each occurrence an alkyl, alkylene, hydroxy or alkoxy group, provided that at least two of said R groups are hydroxy groups.
- the other R groups are usually hydroxy, alkoxy or an alkyl group substituted with an alkoxy, carboxy, hydroxyl, amino or mercapto group.
- the silanes and R groups are selected such that they will form nanoparticles having a size of less than 200nm, preferably less than 100 nm and most preferably less than 50 nm. Particles of a size less than 20 nm are most desirable in most circumstances.
- the silanes are selected so that the nanoparticles will have hydroxyl, amino, mercapto and/or carboxy groups exposed at its surface.
- the silane is desirably selected from the group consisting of vinyltrimethoxysilane, vinyltriethoxysilane, vinylytriacetosilane, ⁇ - glycidoxypropyltrimethoxysilane, ⁇ -methacryloxypropyltrimethoxysilane, ⁇ - aminopropyltrimethoxysilane, ⁇ -aminopropyltriethoxysilane, ⁇ - mercaptopropyltrimethoxysilane, ⁇ -3,4-epoxycyclohexyltrimethoxysilane and phenyltrimethoxysilane.
- the invention further includes a method for forming nanoparticles having covalently bonded photosensitizer. This accomplished by providing reactive intermediate structures on the the nanoparticle, either by providing them on the nanoparticle precursor or by adding them subsequent to nanoparticle formation.
- a specific method for forming such nanoparticles includes the steps of: a) forming a uniform medium comprising from about 70 to about 80 weight percent of a lower alcohol selected from isopropanol, n-butanol, isobutanol and n-pentanol, from about 20 to about 30 weight percent of DMSO, from about 2 to about 3 percent water and from about 0.05 to about 0.15 percent of sufficient surfactant to maintain a dispersion; b) uniformly incorporating one or more silanes, as above described wherein the amount of silane or mixtures of silanes is about the maximum permitted for stability; c) adding sufficient reactive basic compound to form nanoparticles having reactive hydroxyl, amino, mercapto and/or carboxy groups exposed at their surface; d) dialyzing the nanoparticles through a membrane having a pore size of from about 0.1 to about 0.3 ⁇ M; e) during step b) or prior to step d), reacting a photosensitizer
- the surfactant used in the method is usually a polyoxyethylene sorbitan monooleate or sodium dioctyl sulfosucinate and the silane usually includes: vinyltrimethoxysilane, vinyltriethoxysilane, vinylytriacetosilane, ⁇ - glycidoxypropyltrimethoxysilane, ⁇ -methacryloxypropyltrimethoxysilane, ⁇ - aminopropyltrimethoxysilane, ⁇ -aminopropyltriethoxysilane, ⁇ - mercaptopropyltrimethoxysilane, ⁇ -3,4-epoxycyclohexyltrimethoxysilane and phenyltrimethoxysilane.
- the silane is preferably vinyltriethoxysilane or phenyltrimethoxysilane and the basic compound is usually ammonia or 3-aminopropylethoxysilane. It should; however be understood that essentially any base may be used provided that it if it is a strong base, e.g. an alkali hydroxide, it is sufficiently diluted.
- Preferred photosensitizers are preferentially absorbed or adsorbed by cells that require destruction or significant alteration, e.g. cells of hyperproliferative tissue such as tumor cells, hypervascularization such as found in macular degeneration and hyperepidermal debilitating skin diseases.
- Selectivity can be further enhanced by incorporating with nanoparticles in accordance with the present invention, targeting agents such as an monoclonal antibodies, integrin-antagonists or carbohydrates which have high affinity for target tissue (mainly cancer).
- Preferred photosensitizers are tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides, and phthalocyanines and, naphthanocyanines with and without fused ring systems and derivatives of all the above.
- a desirable photosensitizer for many applications is a tumor avid tetrapyrollic photosensitizer, that may be complexed with an element X where X is a metal selected from the group consisting of Zn, In, Ga, Al, or Cu or a radioisotope labeled moiety wherein the radioisotope is selected from the group consisting of 11 C, 18 F, 64 Cu, 124 I, 99 Tc, 111 In and GdIII that may be used in a method for diagnosing, imaging and/or treating hyperproliferative tissue such as tumors and other uncontrolled growth tissues such as found in macular degeneration.
- the photosensitizer may have the generic formula:
- R 9 -OR 1 0 where Ri 0 is lower alkyl of 1 through 8 carbon atoms, -(CH 2 -O) n CH 3 , -(CH 2 ) 2 CO 2 CH 3 , -(CH 2 ) 2 CONHphenyleneCH 2 DTPA,
- R 2 , R 2a , R 3, R 33 , Ri, Rs, Rsa, R7, and R 7a are independently hydrogen, lower alkyl or substituted lower alkyl or two R 2 , R 2a , R 3 , R 3a , R5, Rsa, R7, and R 7a groups on adjacent carbon atoms may be taken together to form a covalent bond or two R 2 , R 2a , R 3 , R 3a , R 5 , R 5a , R 7 , and R 7a groups on the same carbon atom may form a double bond to a divalent pendant group; R 2 and R 3 may together form a 5 or 6 membered heterocyclic ring containing oxygen, nitrogen or sulfur; R 6 is -CH 2 - , -NRn- or a covalent bond; Rs is -(CH 2 ) 2 CO 2 CH 3 , -(CH 2 ) 2 CONHphenyleneCH 2 DTPA,
- R n is -CH 2 CONH-RGD-Phe-Lys, -CH 2 NHCO-RGD-PhC-LyS, a fluorescent dye moiety, or -CH 2 CONHCH 2 CH 2 SO 2 NHCH(CO 2 )CH 2 NHCOPhenylOCH 2 CH 2 NHcycloCNH(CH 2 ) 3 N; and polynuclide complexes thereof; provided that the compound contains at least one integrin antagonist selected from the group consisting of -CH 2 CONH-RGD-Phe-Lys, -CH 2 NHCO- RGD-Phe-Lys and -CH 2 CONHCH 2 CH 2 SO 2 NHCH(CO 2 )CH 2 NHCOPhenylOCH 2 CH 2 NHcycloCNH(CH 2 ) 3 N, where X is a metal selected from the group consisting of Zn, In, Ga, Al, or Cu or a radioisotope labeled moiety wherein the radioisotope is
- the complexes with X are readily made simply by heating the compound with a salt of X such as a chloride.
- the complex will form as a chelate of a -DTPA moiety, when present, or within the tetrapyrollic structure between the nitrogen atoms of the amine structure or both. Examples of such structures are:
- M In, Cu, Ga (with or without radioactive isotope)
- a method for the synthesis of organically modified silica (ORMOSIL) nanoparticles with a covalently linked photosensitizer molecule is provided.
- ORMOSIL organically modified silica
- the nanoconjugated photosensitizer retained its spectral and therapeutic properties, was uptaken by tumor cells in culture and could elicit PDT effect upon photoirradiaion of the targeted cells.
- nanoparticles with covalently incorporated photosensitizer eliminate the possibility of premature release of the photosensitizer molecules while being in circulation and ensure maximum delivery of the photosensitizer to the targeted site.
- ORMOSIL nanoparticles where the photosensitizer molecule is covalently incorporated within the ORMOSIL nanoparticle matrix, have been synthesized and characterized. This has been achieved by the synthesis of iodobenzyl-pyro-silane (Iphotosensitizer), a precursor for ORMOSIL with the linked photosensitizer iodobenzylpyropheophorbide (IP).
- Iphotosensitizer iodobenzyl-pyro-silane
- IP linked photosensitizer iodobenzylpyropheophorbide
- ORMOSIL nanoparticles were synthesized upon co-precipitation of Iphotosensitizer with the commonly used ORMOSIL precursor vinyltriethoxysilane (VTES). This synthesis is carried out in the non-polar core of Tween-80/water microemulsion media. In this microemulsion media, ORMOSIL nanoparticles can readily be synthesized with the combination of Iphotosensitizer and VTES. Photophysical study has demonstrated that the spectroscopic and functional (generation of cytotoxic singlet oxygen) properties of the photosensitizer are preserved in their 'nanoconjugated' state.
- the surfaces of these nanoparticles may, however, be modified using bioconjugation approaches to improve their biocompatibility and biotargeting efficiency.
- the conjugated IP may also be modified with radiolabeled probes (e.g. 1-124) in an effort to combine the feasibiliy of positron-emission tomographic (PET) imaging along with PDT for these nanoparticles.
- PET positron-emission tomographic
- VTES vinyltriethoxysilane
- NANOSEP IOOK OMEGA Microfuge membrane-filters
- N-Ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride, 4- dimethylamino pyridine and 4-(triethoxysilyl)-aniline were purchased from Aldrich and used without further purification.
- 9,10-Anthracenedipropionic acid, disodium salt (ADPA) was purchased from Invitrogen. Colon-26 cells were cultured according to manufacturer's instructions. Unless otherwise mentioned, all cell culture products were obtained from Invitrogen
- the nanoparticles were synthesized by the alkaline hydrolysis and polycondensation of the organo-trialkoxysilane precursors within the non-polar core of Tween-80/water microemulsion. Briefly, to 10 ml of 2% aqueous Tween-80 solution, 300 ⁇ L of co-surfactant 1-butanol was dissolved. To this solution, 40 ⁇ L of a solution (10 mM in DMSO) of Iphotosensitizer (Compound II, Scheme 1) was dissolved by simple magnetic stirring.
- VTES 0 or 40 or 80 or 160 ⁇ L of VTES was added dropwise and the resulting mixture was magnetically stirred for one hour. At this stage, 10DL of aqueous ammonia was added and the resulting solution was magnetically stirred overnight for the formation of the nanoparticles.
- the dialysate containing the IP-conjugated ORMOSIL nanoparticles was sterile filtered (0.2 uM membrane) and was stored at 4 0 C for further use.
- Table 1 represents the amounts of the Iphotosensitizer and VTES used in the various formulations.
- the amount of photosensitizer associated with each fraction could be estimated by reading their optical density at 663 nm (the long wavelength absorption peak for IP/Iphotosensitizer). All subsequent studies with the nanoparticles were carried out with the micelle-free 'retentate' fraction, unless otherwise mentioned.
- TLC Thin-layer chromatography
- TEM Transmission electron microscopy
- the treated cells were washed thoroughly with PBS and then directly imaged using a confocal laser scanning microscope (MRC- 1024, Bio-Rad, Richmond, CA).
- a Ti:sapphire laser (Tsunami from Spectra-Physics) pumped by a diode- pumped solid state laser (Millenia, Spectra Physics) was used as a source of excitation.
- the Ti:sapphire output tuned to 830 nm, was frequency doubled by second harmonic generation (SHG) in a ⁇ -barium borate ( ⁇ -BBO) crystal to obtain the 415-nm light, and was coupled into a single mode fiber for delivery into the confocal scan head.
- SHG second harmonic generation
- ⁇ -BBO ⁇ -barium borate
- a long-pass filter, 585 LP (585 nm), and an additional band pass filter with transmission at 680 ⁇ 15 nm (Chroma 680/30) were used as emission filters for fluorescence imaging.
- Figures IA and IB show the relative optical densities (read at 663 nm, the long-wavelength absorbance peak for IP) of the 'filtrate' and 'retentate' fractions, as well as the non-filtered 'original' samples, for NY-362 through NY-365.
- the non-silylated photosensitizer 3-iodobenzyl-pyro, or EP is used as the control, both dissolved in Tween-80 micelles as well as encaphotosensitizerulated in ORMOSIL nanoparticles.
- a formation of the rigid, spherical and monodisperse nanoparticles with size about 20 nm for NY-363 is shown by TEM (Fig.l,B). It is worth noting that while TEM of NY-362 showed no formation of nanoparticles, thus confirming inability of Iphotosensitizer alone to form nanoparticles, NY-364 and NY-365 both formed the same-sized nanoparticles as NY-363 (data not shown), showing that the size of the nanoparticles is unaffected by the amount of the precursor used.
- Intensity of the singlet oxygen emission sensitized in all suspensions of nanoparticles / micelles correlates with fluorescence intensity (Figure 3B). Intensity of 1 O 2 emission as well as fluorescence intensity that was almost identical for NY-363, NY-364, NY-365. IP/Tween-80 micellar suspension shows slightly higher fluorescence and 1 O 2 emission intensities, whereas intensity for NY-362 (non-spin-filtered) is lower. [0073] Correlation of the fluorescence and 1 O 2 emission intensities confirms aggregation affecting singlet oxygen generation.
- FIG. 4B results on singlet oxygen production, which were obtained with method of ADPA bleaching, showed remarkable similarity to those obtained by singlet oxygen phosphorescence spectroscopy ( Figure 4B), following the same trend: IP/Tween-80 micellar suspension demonstrated higher 1 O 2 generation then NY-363, NY-364, NY-365, whereas intensitiy for NY-362 is lower. This means that singlet oxygen generated within nanoparticles is mostly deactivated outside nanoparticles, causing bleaching of ADPA. In this case, lifetime of the singlet oxygen generated within nanoparticles should be determined by the water environment and be around 4 ⁇ s. 13 [0076]
- Figure 5 is a graph showing decays of emission at 1270 nm. Signal obtained for the suspension of neat ORMOSIL nanoparticles (100% of VTES) was used as Instrument Response Function (IRF). Rose Bengal (RB) in methanol was used as a reference standard producing singlet oxygen. Figure 5 shows decays of the emission from
- Iphotosensitizer/VTES are very close to that sensitized by IP/Tween-80 micellar suspension and have average lifetime ( ⁇ ) in the range of 4.5-5 ⁇ s.
- ⁇ average lifetime
- decay of 1 O 2 emisssion sensitized by RB in methanol is also shown, demonstrating monoexponential fitting with ⁇ wlO ⁇ s, which is characteristic lifetime for 1 O 2 in methanol. 13
- Rise time of the 1 O 2 emission sensitized by the nanoparticle / micellar suspensions is noticeably higher then for RB molecular solution, including time of diffusion of the molecular oxygen to the incorporated photosensitizer chromophores.
- FIG. 6 is a plurality of micrographs showing cellular uptake Colon-26 cells treated overnight with NY-363 (A), NY-364 (B), NY-365 (C). Transmission (above) and fluorescence (below) channels are shown. Confocal pinhole and PMT gain remained same during imaging.
- FIG. 7 A structural representation of a nanoparticle in accordance with the invnetion is shown in Figure 7.
- Ri labeled photosensitizer
- P unlabeled
- a modified formulation of the nanoparticles is provided with the photosensitizer molecule being covalently linked, instead of just being physically encaphotosensitizerulated.
- the photosensitizer molecule being covalently linked, instead of just being physically encaphotosensitizerulated.
- nanoparticle conjugated (covalently linked) photosensitizers have been demonstrated having simple preparation that eliminate the possibility of premature release of the photosensitizer to unwanted sites in vivo.
- the invention permits ease of active targeting by attaching targeting grouphotosensitizer on the particle surface
- the composite contains a covalently linked radioactive atoms for PET/SPECT imaging or magnetic resonance imaging contrast agents (i.e gadolinium).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Nanoparticles containing covalently linked photosensitizer molecules that overcome the drawback of premature release and thus enhance the outcome of PDT. [Silica-based nanoparticles are provided containing at least one covalently linked photosensitizer. The photosensitizer is preferably a tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides, and phthalocyanines, naphthanocyanines with and without fused ring systems and derivatives of all the above. The nanoparticle may also include covalently linked imaging agents, e.g. radionuclides, magnetic resonance (MR) and fluorescence imaging agents. The imaging agents and photosensitizers may be at a periphery (surface) of the nanoparticles to increase efficiency. Target-specific nanoparticles may be provided by incorporating biotargeting molecules such as specific antibodies at the surface that react with particular ligands to obtain target specificity. Diagnostic agents may be present in the antibody in addition to imaging agents and tumor specific photosensitizers.
Description
ORGANICALLY MODIFIED SILICA NANOPARTICLES WITH COVALENTLY INCORPORATED PHOTOSENSITIZERS FOR DRUG DELIVERY IN PHOTODYNAMIC THERAPY
BACKGROUND OF THE INVENTION
[0001] The present invention relates to the field of nanoparticle mediated drug delivery in photodynamic therapy. Photodynamic therapy (PDT), a light-activated treatment for cancer and other diseases, has emerged as one of the important areas in biophotonics research. PDT utilizes light-sensitive drugs or photosensitizers (PS), which are preferentially localized in malignant tissues upon systemic administration. The therapeutic effect is activated by the photoexcitation of the localized photosensitizers and the subsequent generation of cytotoxic species, such as singlet oxygen (1O2), free radicals or peroxides, which lead to selective and irreversible destruction of the diseased tissues without damaging adjacent healthy ones.
[0002] In spite of the advantages over current treatments including surgery, radiation therapy and chemotherapy, PDT still has problems to be resolved for a more general clinical acceptance. One of the major challenges in PDT is the preparation of stable pharmaceutical formulations of photosensitizers for systemic administration. Since most existing photosensitizers are poorly water soluble, they aggregate easily under physiological conditions and thus cannot be simply injected intravenously. Moreover, even with water- soluble photosensitizers, the accumulation selectivity for diseased tissues is not high enough for clinical use. [0003] Photodynamic therapy (PDT) is based on the concept that certain therapeutic molecules called photosensitizers (photosensitizer) can be preferentially localized in malignant tissues, and when these photosensitizers are activated with appropriate wavelength of light, they pass on their excess energy to surrounding molecular oxygen resulting in the generation of reactive oxygen species (ROS), such as free radicals and singlet oxygen (1O2), which are toxic to cells and tissues.
[0004] PDT is a non-invasive treatment and used for several types of cancers, and its advantage lies in the inherent dual selectivity. First, selectivity is achieved by a preferential localization of the photosensitizer in target tissue (e.g. cancer), and second, the photoirradiation and subsequent photodynamic action can be limited to a specific area. Since
the photosensitizer is non-toxic without light exposure, only the irradiated areas will be affected, even if the photosensitizer does infiltrate normal tissues.
[0005] Although PDT is emerging as a choice of treatment for many cancer patients, because of the hydrophobic nature of the most of the photosensitizers, searches are still on for developing an ideal photosensitizer formulation that can be easily injectable in vivo. Numerous approaches have been proposed to achieve not only stable aqueous dispersion but also site-specific and time-controlled delivery of therapeutic agents, often using a biocompatible delivery vehicle. Colloidal carriers for photosensitizers, such as oil- dispersions, liposomes, low-density lipoproteins, polymeric micelles, and recently ceramic nanoparticles are examples of delivery shuttles for photosensitizer molecules some of which may offer benefits from rendering aqueous stability and appropriate size for passive targeting to tumor tissues by the "enhanced permeability and retention" (EPR) effect, offering a possibility of bioconjugation approaches to enhance bioavailability as well as tumor targeting and offering a possibility of actively targeting tumor tissues by appropriate surface functionalization.
[0006] In PDT the release of the photosensitizer drugs is not a prerequisite for their therapeutic action (unlike in conventional chemotherapy), and the premature release of the photosensitizer molecules from carrier vehicles while in systemic circulation results in reduced efficacy of treatment. [0007] Nanoparticles made of an organically modified silica complexed with polynucleotides have been described in co-pending United States priority application 11/195,066. That patent application does not, however, suggest anything concerning nanoparticles made of an organically modified silica complexed with a photodynamic agent.
BRIEF DESCRIPTION OF THE INVENTION
[0008] In accordance with the invention, nanoparticles containing covalently linked photosensitizer molecules are provided to overcome the drawback of their premature release and thus enhance the outcome of PDT.
[0009] In accordance with the invention, silica-based nanoparticles are provided containing at least one covalently linked photosensitizer. The photosensitizer is preferably a tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides, and phthalocyanines, naphthanocyanines with and without fused ring systems and derivatives of all the above.
[0010] The nanoparticle may also include covalently linked imaging agents, e.g. radionuclides, magnetic resonance (MR) and fluorescence imaging agents. The imaging agents and photosensitizers may be at a periphery (surface) of the nanoparticles to increase efficiency. [0011] Target-specific nanoparticles may be provided by incorporating biotargeting molecules such as specific antibodies at the surface that react with particular ligands to obtain target specificity. Diagnostic agents may be present in the antibody in addition to imaging agents and tumor specific photosensitizers as previously and subsequently discussed. [0012] In general, the nanoparticle of the invention has the structural formula:
where the ring represents a silicone polymer matrix, where R4 is (Ri)n-R2 -(Rs)n where Ri is a labeled photosensitizer (IP) or unlabeled photosensitizer (P), cyanine dye, SPECT imaging agent, PET imaging agent, MR imaging agent or fluorescent imaging agent at least partially available at a surface of the silicone polymer matrix; R2 is -O-, -COO-, -NR5 or -NH- connected to the silicone polymer matrix directly or through an intermediate group, n is 0 or 1; provided that at least one n is 1 and R3 is cyanine dye, SPECT, PET, MR or fluorescent imaging agent, linked targeting agent RGD, F3 peptide, carbohydrate or folic acid or labeled photosensitizer (IP) or unlabeled photosensitizer (P) embedded in the silicone polymer matrix, and R5 is lower alkyl of from 1 to 5 carbon atoms where a plurality of Ri groups, R3 groups or mixtures thereof are photosensitizer and/or labeled photosensitizer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure IA shows graphic results of spin-filtration of various formulations of
PS/nanoparticles. The graph shows the relative optical densities (read at 663 nm, the long- wavelength absorbance peak for IP) of the 'filtrate' and 'retentate' fractions, as well as the non-filtered 'original' samples, for cell lines NY-362 through NY-365. The non-silylated photosensitizer 3-iodobenzyl-pyro, or EP (compound I, Scheme 1), is used as the control, both dissolved in Tween-80 micelles as well as encaphotosensitizerulated in ORMOSIL nanoparticles. [0014] Figure IB shows a TEM image of NY-363. [0015] Figure 1C shows a scheme 1 for synthesis of the precursor 3-iodobenzylpyro- silane (EPS) shown as compound II. The non-silylated photosensitizer 3-iodobenzyl-pyro starting compound, or IP (compound I), is used as the control, both dissolved in Tween-80 micelles as well as encapsulated in ORMOSEL nanoparticles. [0016] Figure 2 shows emission of EP upon UV irradiation following TLC of EP- conjugated (lane 1) and encapsulated (lane 2) ORMOSlL nanoparticles. Lane 3 shows the same for EP/1 % Tween-80.
[0017] Figure 3A shows absorption spectra of the "micelle free" nanoparticle samples (retentate collected after spin-filtration and resuspended), as well as non-filtered micellar suspensions of EP/Tween-80 and NY-362 (100% of EPS, no VTES). Fluorescence was obtained on exciting the molecule at 514 nm.
[0018] Figure 3B shows fluorescence spectra of the "micelle free" nanoparticle samples (retentate collected after spin-filtration and resuspended), as well as non-filtered micellar suspensions of EP/Tween-80 and NY-362 (100% of EPS, no VTES). Fluorescence was obtained on exciting the molecule at 514 nm. [0019] Figure 4A shows results on singlet oxygen production by "micelle-free" suspensions of nanoparticles which were obtained by singlet oxygen phosphorescence spectroscopy, showing remarkable similarity to those obtained following the same trend: EP/Tween-80 micellar suspension demonstrated higher 1O2 generation than NY-363, NY-364, NY-365; whereas, intensitiy for NY-362 is lower. [0020] Figure 4B shows results on singlet oxygen production by "micelle-free" suspensions of nanoparticles, obtained using an ADPA (anthracenedipropionic acid) bleaching method. Non-spin-filtered micellar suspensions of EP/Tween-80 and NY-362 (100% of Iphotosensitizer, no VTES) were used as controls. Rose Bengal (RB) in methanol was used as a reference standard for the 1O2 phosphorescence measurements. This means
that singlet oxygen generated within nanoparticles is mostly deactivated outside nanoparticles, causing bleaching of ADPA. Irradiation with 514 nm, applied laser power was 5 times higher for the bleaching experiment than for spectra acquisition. [0021] Figure 5 shows decays of the emission from Iphotosensitizer/VTES nanoparticle and IP Tween-80 suspensions at 1270 nm.
[0022] Figure 6 shows combined comparative photomicrographs Figure 6 of Colon-
26 cells treated overnight with NY-363 (A), NY-364 (B), NY-365 (C). Transmission (above) and fluorescence (below) channels are shown. Confocal pinhole and PMT gain remained same during imaging. [0023] Figure 7 shows a nonoparticle 10 having R4 groups where the ring represents a silicone polymer matrix. R4 is (Rt)n-R2 -(Rs)n . Ri is a labeled photosensitizer (IP) or unlabeled photosensitizer (P), cyanine dye, SPECT imaging agent, PET imaging agent, MR imaging agent or fluorescent imaging agent at least partially available at a surface of the silicone polymer matrix. R2 is -O-, -COO-, -NR5 or -NH- connected to the silicone polymer matrix directly or through an intermediate group, n is 0 or 1; provided that at least one n is 1. R3 is cyanine dye, SPECT, PET, MR or fluorescent imaging agent, linked targeting agent RGD, F3 peptide, carbohydrate or folic acid or labeled photosensitizer (IP) or unlabeled photosensitizer (P) embedded in the silicone polymer matrix. R5 is lower alkyl of from 1 to 5 carbon atoms where a plurality of Ri groups, R2 groups or mixtures thereof are photosensitizer and/or labeled photosensitizer.
[0024] Figure 8A shows a structure where P is a photosensitizer, e.g. pophyrins, chlorins, bacteriochlorins, phthalocyanines with and without fused structures, R = OH, COOH, NH2 groups, and/or R= imaging agent, e.g. PET, MR, or fluorescence imaging agents and/or R = targeting agent, e.g. RGD, F3 peptides, carbohydrates and folic acid. [0025] Figure 8B shows a structure where X = I124-labeled photosensitizer (IP), cyanine dye, SPECT imaging agent, MR imaging agent and P = photosensitizer. [0026] Figure 8C shows a structure where X = I124-labeled photosensitizer (IP), cyanine dye, SPECT imaging agent, MR imaging agent, R = OH, COOH, or NH2 groups that may be linked by reaction with targetingents, e.g. RGD, F3 peptides, carbohydrates and folic acid.
DETAILED DESCRIPTION OF THE INVENTION
[0027] In accordance with the invention, nanoparticles containing covalently linked photosensitizer molecules are provided to overcome the drawback of their premature release and thus enhance the outcome of PDT. [0028] As previously discussed, in accordance with the invention, silica-based nanoparticles are provided containing at least one covalently linked photosensitizer. The photosensitizer is preferably a tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides. [0029] Specific ezamples of such photosensitizers may, for example be found in U.S.
Patent Nos. 4,649,151; 4,866,168; 4,932,934; 4,961,920; 5,002,962; 5,015,463; 5,028,621; 5,093,349; 5,145,863; 5,171,741; 5,173,504; 5,190,966; 5,198,460; 5,225,433; 5,257,970; 5,314,905; 5,459,159; 5,498,710; 5,591,847; 5,770,730; 5,952,366; 6,624,187 and 6,849,607, and phthalocyanines, naphthanocyanines with and without fused ring systems and derivatives of all the above.
[0030] The nanoparticle may also include covalently linked imaging agents, e.g. radionuclides, magnetic resonance (MR) and fluorescence imaging agents. The imaging agents and photosensitizers may be at a periphery (surface) of the nanoparticles to increase efficiency. [0031] Target-specific nanoparticles may be provided by incorporating biotargeting molecules such as specific antibodies at the surface that react with particular ligands to obtain target specificity. Diagnostic agents may be present in the antibody in addition to imaging agents and tumor specific photosensitizers as previously and subsequently discussed.
[0032] In general, the nanoparticle of the invention has the structural formula:
where the ring represents a silicone polymer matrix.
[0033] R4 is (Ri)n-R2 -(Rs)n where Ri is a labeled photosensitizer (IP) or unlabeled photosensitizer (P), cyanine dye, SPECT (single proton emission computed tomography) imaging agent, PET (positron emission tomography) imaging agent, MR imaging agent or fluorescent imaging agent at least partially available at a surface of the silicone polymer matrix.
[0034] At least one Ri or R3 group may be a tetrapyrollic photosensitizer, e.g. porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrins, pheophorbides including pyropheophorbides, and derivatives thereof. [0035] R2 is -O-, -COO-, -NR5 or -NH- connected to the silicone polymer matrix directly or through an intermediate group. The intermediate group may, for example, be subtituted or unsubstituted alkylene or phenylene. The alkylene or phenylene may be substituted with at least one hydroxy, carboxy, amino, sulfo, alkylester, alkylether, heterocyclo, or halo group. [0036] n is 0 or 1 ; provided that at least one n is 1. [0037] R3 is cyanine dye, SPECT, PET, MR or fluorescent imaging agent, linked targeting agent RGD, F3 peptide, carbohydrate or folic acid or labeled photosensitizer (IP) or unlabeled photosensitizer (P) embedded in the silicone polymer matrix. RGD is a peptide that contains the Arg-Gly-Asp attachment site that recognizes v3 and v5 integrin receptors
that play a role in angiogenesis, vascular intima thickening and proliferation of malignant tumors.
[0038] R5 is lower alkyl of from 1 to 5 carbon atoms. A plurality of Ri groups, R3 groups or mixtures thereof are photosensitizer and/or labeled photosensitizer. [0039] The Ri or R3 group may be phthalocyanine, naphthanocyanine and derivatives thereof and may also be a radionuclide or MR or fluorescencent imaging agent. A plurality of Ri groups are preferably photosensitizers located at peripheral positions on the nanoparticle and a plurality of R3 groups are imaging agents located at peripheral positions on the nanoparticle. [0040] The nanoparticle are desirably provided with biotargeting molecules following suitable surface functionalization to obtain target-specific nanoparticles. Examples of such biotargeting molecules are antibodys and the suitable surface functionalization for the antibody is a ligand, e.g. RGD and F3 peptide.. [0041] The nanoparticle may further include at least one diagnostic agent. [0042] "Photosensitiers" (PS) as used herein means any material that can enter or attach to a cell or portion thereof and be activated by eletromagnetic radiation, usually light, to destroy the cell or significantly alter its activity.
[0043] "nanoparticles made of an organically modified silica" as used herein refers to nanoparticles made from silica that has been organically modified to self organize into polysicone nanoparticles upon precipitation from solution. Preferred organically modified silica nanoparticles are ORMOSIL nano particles usually made by inclusion of a vinyltriethoxysilane in a sufactant solution followed by precipitation with ammonia or other amine, e.g. 3 aminopropyltriethoxy silane. In the first case the nanoparticle has surface -OH groups and in the second case has surface amino groups. [0044] The silane (silicone) matrix is formed by self reaction of hydroxy silanes by dehydration to form a polymeric silicone matrix of silcon atoms interconnected by oxygen atoms. The starting silanes have the formula R4Si where R is independently at each occurrence an alkyl, alkylene, hydroxy or alkoxy group, provided that at least two of said R groups are hydroxy groups. The other R groups are usually hydroxy, alkoxy or an alkyl group substituted with an alkoxy, carboxy, hydroxyl, amino or mercapto group. The silanes and R groups are selected such that they will form nanoparticles having a size of less than 200nm, preferably less than 100 nm and most preferably less than 50 nm. Particles of a size less than 20 nm are most desirable in most circumstances. The silanes are selected so that the
nanoparticles will have hydroxyl, amino, mercapto and/or carboxy groups exposed at its surface.
[0045] The silane is desirably selected from the group consisting of vinyltrimethoxysilane, vinyltriethoxysilane, vinylytriacetosilane, γ- glycidoxypropyltrimethoxysilane, γ-methacryloxypropyltrimethoxysilane, γ- aminopropyltrimethoxysilane, γ-aminopropyltriethoxysilane, γ- mercaptopropyltrimethoxysilane, γ-3,4-epoxycyclohexyltrimethoxysilane and phenyltrimethoxysilane.
[0046] The invention further includes a method for forming nanoparticles having covalently bonded photosensitizer. This accomplished by providing reactive intermediate structures on the the nanoparticle, either by providing them on the nanoparticle precursor or by adding them subsequent to nanoparticle formation. [0047] A specific method for forming such nanoparticles includes the steps of: a) forming a uniform medium comprising from about 70 to about 80 weight percent of a lower alcohol selected from isopropanol, n-butanol, isobutanol and n-pentanol, from about 20 to about 30 weight percent of DMSO, from about 2 to about 3 percent water and from about 0.05 to about 0.15 percent of sufficient surfactant to maintain a dispersion; b) uniformly incorporating one or more silanes, as above described wherein the amount of silane or mixtures of silanes is about the maximum permitted for stability; c) adding sufficient reactive basic compound to form nanoparticles having reactive hydroxyl, amino, mercapto and/or carboxy groups exposed at their surface; d) dialyzing the nanoparticles through a membrane having a pore size of from about 0.1 to about 0.3 μM; e) during step b) or prior to step d), reacting a photosensitizer with a reactive group on the surface of the nanoparticles.
[0048] The surfactant used in the method is usually a polyoxyethylene sorbitan monooleate or sodium dioctyl sulfosucinate and the silane usually includes: vinyltrimethoxysilane, vinyltriethoxysilane, vinylytriacetosilane, γ- glycidoxypropyltrimethoxysilane, γ-methacryloxypropyltrimethoxysilane, γ- aminopropyltrimethoxysilane, γ-aminopropyltriethoxysilane, γ- mercaptopropyltrimethoxysilane, γ-3,4-epoxycyclohexyltrimethoxysilane and phenyltrimethoxysilane.
[0049] The silane is preferably vinyltriethoxysilane or phenyltrimethoxysilane and the basic compound is usually ammonia or 3-aminopropylethoxysilane. It should; however be
understood that essentially any base may be used provided that it if it is a strong base, e.g. an alkali hydroxide, it is sufficiently diluted.
[0050] Preferred photosensitizers are preferentially absorbed or adsorbed by cells that require destruction or significant alteration, e.g. cells of hyperproliferative tissue such as tumor cells, hypervascularization such as found in macular degeneration and hyperepidermal debilitating skin diseases. Selectivity can be further enhanced by incorporating with nanoparticles in accordance with the present invention, targeting agents such as an monoclonal antibodies, integrin-antagonists or carbohydrates which have high affinity for target tissue (mainly cancer). [0051] Preferred photosensitizers are tetrapyrrole-based compounds related to porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrin derivatives, pheophorbides including pyropheophorbides, and phthalocyanines and, naphthanocyanines with and without fused ring systems and derivatives of all the above. [0052] A desirable photosensitizer for many applications is a tumor avid tetrapyrollic photosensitizer, that may be complexed with an element X where X is a metal selected from the group consisting of Zn, In, Ga, Al, or Cu or a radioisotope labeled moiety wherein the radioisotope is selected from the group consisting of 11C, 18F, 64Cu, 124I, 99Tc, 111In and GdIII that may be used in a method for diagnosing, imaging and/or treating hyperproliferative tissue such as tumors and other uncontrolled growth tissues such as found in macular degeneration.
[0053] More particularly, the photosensitizer may have the generic formula:
In the case of the presence of a tetrapyrollic photosensitizer, it usually has the structural formula:
where R9 = -OR10 where Ri0 is lower alkyl of 1 through 8 carbon atoms, -(CH2-O)nCH3, -(CH2)2CO2CH3, -(CH2)2CONHphenyleneCH2DTPA,
-CH2CH2CONH(CONHphenyleneCH2DTPA)2 , -CH2R1, or \ , or a
O=C
R 1 i "N ~R i 1
fluorescent dye moiety; R2, R2a, R3, R33, Ri, Rs, Rsa, R7, and R7a are independently hydrogen, lower alkyl or substituted lower alkyl or two R2, R2a, R3, R3a, R5, Rsa, R7, and R7a groups on adjacent carbon atoms may be taken together to form a covalent bond or two R2, R2a, R3, R3a, R5, R5a, R7, and R7a groups on the same carbon atom may form a double bond to a divalent pendant group; R2 and R3 may together form a 5 or 6 membered heterocyclic ring containing oxygen, nitrogen or sulfur; R6 is -CH2-, -NRn- or a covalent bond; Rs is -(CH2)2CO2CH3, -(CH2)2CONHphenyleneCH2DTPA,
-CH2CH2CONH(CONHphenyleneCH2DTPA)2, -CH2Rn Or 0_J, where
R 1 i "N ' R i 1
Rn is -CH2CONH-RGD-Phe-Lys, -CH2NHCO-RGD-PhC-LyS, a fluorescent dye moiety, or -CH2CONHCH2CH2SO2NHCH(CO2)CH2NHCOPhenylOCH2CH2NHcycloCNH(CH2)3N; and polynuclide complexes thereof; provided that the compound contains at least one integrin antagonist selected from the group consisting of -CH2CONH-RGD-Phe-Lys, -CH2NHCO- RGD-Phe-Lys and -CH2CONHCH2CH2SO2NHCH(CO2)CH2NHCOPhenylOCH2CH2NHcycloCNH(CH2)3N, where X is a metal selected from the group consisting of Zn, In, Ga, Al, or Cu or a radioisotope labeled moiety wherein the radioisotope is selected from the group consisting of 11C, 18F, 64Cu, 124I, 99Tc, 111In and GdIII .
[0054] The complexes with X are readily made simply by heating the compound with a salt of X such as a chloride. The complex will form as a chelate of a -DTPA moiety, when present, or within the tetrapyrollic structure between the nitrogen atoms of the amine structure or both. Examples of such structures are:
M = 2H or
M = In, Cu, Ga (with or without radioactive isotope)
and
M = 2H or
M = In, Cu, Ga (with or without radioactive isotope) Where X=M
[0055] In accordance with the invention a method is provided for the synthesis of organically modified silica (ORMOSIL) nanoparticles with a covalently linked photosensitizer molecule. The nanoconjugated photosensitizer retained its spectral and therapeutic properties, was uptaken by tumor cells in culture and could elicit PDT effect upon photoirradiaion of the targeted cells.
[0056] In accordance with the invention, it has been possible to prepare a highly stable aqueous formulation of organically modified silica (ORMOSIL) nanoparticles
encaphotosensitizerulating (photosensitizer encapsulating) the hydrophobic photosensitizer, where the encaphotosensitizerulated photosensitizer is able to generate singlet oxygen upon photoactivation owing to the free diffusion of molecular oxygen across the ORMOSIL matrix. However, because of mesoporosity of the ORMOSIL matrix, encaphotosensitizerulation of photosensitizer does not exclude the photosensitizer release during in vivo circulation. In accordance with the present invention, nanoparticles with covalently incorporated photosensitizer eliminate the possibility of premature release of the photosensitizer molecules while being in circulation and ensure maximum delivery of the photosensitizer to the targeted site. [0057] In particular, ORMOSIL nanoparticles, where the photosensitizer molecule is covalently incorporated within the ORMOSIL nanoparticle matrix, have been synthesized and characterized. This has been achieved by the synthesis of iodobenzyl-pyro-silane (Iphotosensitizer), a precursor for ORMOSIL with the linked photosensitizer iodobenzylpyropheophorbide (IP). Highly monodispersed aqueous dispersion of ORMOSIL nanoparticles (average diameter ~20 nm) were synthesized upon co-precipitation of Iphotosensitizer with the commonly used ORMOSIL precursor vinyltriethoxysilane (VTES). This synthesis is carried out in the non-polar core of Tween-80/water microemulsion media. In this microemulsion media, ORMOSIL nanoparticles can readily be synthesized with the combination of Iphotosensitizer and VTES. Photophysical study has demonstrated that the spectroscopic and functional (generation of cytotoxic singlet oxygen) properties of the photosensitizer are preserved in their 'nanoconjugated' state. These nanoparticles are found to be uptaken by tumor cells in culture, thus demonstrating the potential of these nanoparticles for PDT of cancer. [0058] Confocal bioimaging studies have revealed that the in vitro cellular uptake between these IP-conjugated nanoparticles is weaker when compared to that of the free IP (i.e. IP in Tween-80).This weak cellular uptake is also reflected in the in vitro PDT efficacy of the IP-conjugated nanoparticles, which is again found to be weaker than that of the free IP. This weak cellular uptake, however, can be substantially improved by modifying the surface of these nanoparticles. The surfaces of these nanoparticles may, however, be modified using bioconjugation approaches to improve their biocompatibility and biotargeting efficiency. The conjugated IP may also be modified with radiolabeled probes (e.g. 1-124) in an effort to combine the feasibiliy of positron-emission tomographic (PET) imaging along with PDT for these nanoparticles.
[0059] In vitro experiments have revealed that these nanoparticles are avidly uptaken by tumor cells, demonstrating the potential for using them as drug-carriers in PDT. [0060] The materials used in the examples discussed herein are commercially available and found in many laboratories throughout the world and/or are readily prepared by those skilled in the art. ORMOSIL precursor vinyltriethoxysilane (VTES) was purchased from Sigma-Aldrich. Microfuge membrane-filters (NANOSEP IOOK OMEGA) are a product of Pall Corporation. N-Ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride, 4- dimethylamino pyridine and 4-(triethoxysilyl)-aniline were purchased from Aldrich and used without further purification. 9,10-Anthracenedipropionic acid, disodium salt (ADPA) was purchased from Invitrogen. Colon-26 cells were cultured according to manufacturer's instructions. Unless otherwise mentioned, all cell culture products were obtained from Invitrogen
[0061] Synthesis of Iodobenzyl-pyro-Silane (Iphotosensitizer): The synthesis of
Iphotosensitizer is shown in Figure 1C (Scheme 1). First, 3-iodobenzyl-pyro (Compound I, 50.0 mg, 0.065 mmol) was taken in a dry round bottom flask (RBF) (100 ml) and dissolved in dry dichloromethane (30 ml). To this, 4-(triethoxysilyl)-aniline (19.9 mg, 0.078 mmol), N- Ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride (24.9 mg, 0.13 mmol) and 4- dimethylamino pyridine (15.8 mg, 0.13 mmol) were added and the resultant mixture was stirred for 14 hr at room temperature under N2 atmosphere. Reaction mixture was then diluted with dichloromethane (100 ml) and washed with brine (50 ml). Then, the organic layer was separated, dried over sodium sulfate and concentrated. Finally, product (Iphotosensitizer, Compound II) was purified over silica gel plate using 2.5% methanol-dichloromethane as mobile phase. Yield: 35.0 mg (53.4%). NMR spectra were recorded on a Bruker DRX 400 MHz spectrometer at 303K in CDCl3 solution and referenced to residual CHCU (7.26 ppm). 1HNMR (400Mhz, CDCl3): δ 9.80 (splitted singlet, IH, meso-H), 8.78 (splitted singlet, IH, meso-H), 8.55 (splitted singlet, IH, meso-H), 7.81 (d, IH, Ar-H, J = 17.6 Hz), 7.65 (t, IH, Ar-H, J = 8.0 Hz), 7.57 (m, IH, Ar-H), 7.50 (m, 2H, Ar-H), 7.34-7.29 (m, 3H, Ar-H), 7.08 (m, IH, Ar-H), 6.00 (m, IH, CH3CHOAr), 5.34 (d, IH, 15'-CH2, J = 19.6 Hz), 5.10 (d, IH, 15'-CH2, J = 19.6 Hz), 4.72 (m, IH, H-17), 4.59 (m, 2H, OCH2-Ar), 4.41 (m, IH, H-18), 3.83 (q, 6H, SiOCH2-CH3, J = 7.2 Hz), 3.55 (m, IH, 8-CH2CH3), 3.37 (m, IH, 8-CH2CH3), 3.34 (splitted singlet, 3H, ring-CH3), 3.24 (splitted singlet, 3H, ring-CH3), 2.81 (m, IH, 172-CHA 2.72 (m, IH, 17^CH2), 2.66 (splitted singlet, 3H, ring-CH3), 2.36 (m, IH, 17'-CH2), 2.24 (m, IH, 17'-CH2), 2.21 (m, 3H, CH3CH-OAr), 1.81 (d, 3H, 18-CH3, J = 7.2 Hz), 1.53 (m, 3H, 8-
CH2CH3), 1.20 (t, 9H, SiOCH2-CH3, J = 6.8 Hz), 0.45 (brs, IH, NH), -1.53 (brs, IH, NH). EMS: 1007 (M++l).
[0062] Synthesis and characterization of the covalently linked iodobenzylether-pyro nanoparticles. In general, the nanoparticles were synthesized by the alkaline hydrolysis and polycondensation of the organo-trialkoxysilane precursors within the non-polar core of Tween-80/water microemulsion. Briefly, to 10 ml of 2% aqueous Tween-80 solution, 300 μL of co-surfactant 1-butanol was dissolved. To this solution, 40 μL of a solution (10 mM in DMSO) of Iphotosensitizer (Compound II, Scheme 1) was dissolved by simple magnetic stirring. Next, 0 or 40 or 80 or 160 μL of VTES was added dropwise and the resulting mixture was magnetically stirred for one hour. At this stage, 10DL of aqueous ammonia was added and the resulting solution was magnetically stirred overnight for the formation of the nanoparticles. In order to study the difference of conjugated photosensitizer in ORMOSIL, as opposed to encaphotosensitizerulated photosensitizer in ORMOSIL, we also synthesized photosensitizer encaphotosensitizerulated nanoparticles by an identical procedure as described above, except that 40 μL of 10 mM DMSO solution of IP (Compound I, Scheme 1) was used instead of Iphotosensitizer Next, the nanoparticles were dialyzed overnight against distilled water using a cellulose membrane of cut-off pore size of 12-14 kD for the removal of unreacted molecules. The dialysate containing the IP-conjugated ORMOSIL nanoparticles was sterile filtered (0.2 uM membrane) and was stored at 40C for further use. Table 1 represents the amounts of the Iphotosensitizer and VTES used in the various formulations.
Table 1. Formulations of the Iphotosensitizer nanoparticles [0063] To separate the Tween-80 micelles (and any associated photosensitizer) from the nanoparticles, the dialyzed dispersions were filtered in a microfuge membrane-filter (NANOSEP IOOK OMEGA, Pall Corporation, USA) by centrifuging at 14,000 rpm for 30 minutes (spin-filtration). Tween-80 micelles and their associated photosensitizer molecules flowed through this membrane and are collected in the lower tube (fliltrate), while nanoparticles got embedded in the membrane and could be subsequently extracted by adding
water and sonicating/vortexing briefly (retentate). The amount of photosensitizer associated with each fraction could be estimated by reading their optical density at 663 nm (the long wavelength absorption peak for IP/Iphotosensitizer). All subsequent studies with the nanoparticles were carried out with the micelle-free 'retentate' fraction, unless otherwise mentioned.
[0064] Thin-layer chromatography (TLC) was done on ANALTECH pre-coated silica gel GF PE sheets (Cat. 159017, layer thickness 0.25 mm). Preparative TLC plates used for the purification (ANALTECH pre-coated silica gel GF glass plate, Cat. 02013, layer thickness 1.0 mm). Dichloromethane was dried over P2Os under N2 atmosphere. [0065] Characterization of size, shape and functionality of the nanoparticles.
Transmission electron microscopy (TEM) was performed to determine the size and shape of the prepared nanoparticles, using a JEOL JEM-100cx microscope at an accelerating voltage of 80 kV. UV-visible absorption spectra were acquired using a Shimadzu UV-3600 spectrophotometer, in a quartz cuvette with 1 cm path length. Fluorescence spectra were recorded on a Fluorolog-3 spectrofluorometer (Jobin Yvon, Longjumeau, France). Generation of singlet oxygen (1O2) was detected by its phosphorescence emission peaked at 1270 nm.8"10 A SPEX 270M Spectrometer (Jobin Yvon) equipped with a Hamamatsu ER-PMT was used for recording singlet oxygen phosphorescence. The sample solution in a quartz cuvette was placed directly in front of the entrance slit of the spectrometer and the emission signal was collected at 90-degrees relative to the exciting laser beam. An additional longpass filters (a 950LP filter and a 538AELP filter, both from Omega Optical) were used to attenuate the scattered light and fluorescence from the samples. 1O2 phosphorescence decays at 1270 nm were acquired using Infinium oscilloscope (Hewlett-Packard) coupled to the output of the PMT. A second harmonic (532 nm) from nanosecond pulsed Nd:YAG laser (Lotis TII, Belarus) operating at 20 Hz was used as the excitation source.
[0066] Chemical oxidation of ADPA in the nanoparticle water dispersions was used as an independent method to characterize singlet oxygen generation efficiency.8 In this case, a decrease in the absorbance of the ADPA added to nanoparticle water suspension was monitored as a function of time, following irradiation with 514 nm. [0067] In Vitro Studies with Tumor Cells: Nanoparticle Uptake and Imaging. For studying nanoparticles uptake and imaging, Colon-26 cells were used, maintained in RPMI- 1640 media with 10% fetal bovine serum (FBS) and appropriate antibiotic. The cells at a confluency of 70-75 % were treated overnight with the nanoparticles at a final photosensitizer concentration of 2 DM. Next day, the treated cells were washed thoroughly with PBS and
then directly imaged using a confocal laser scanning microscope (MRC- 1024, Bio-Rad, Richmond, CA). A water immersion objective lens (Nikon, Fluor-60X, NA=LO) was used for cell imaging. A Ti:sapphire laser (Tsunami from Spectra-Physics) pumped by a diode- pumped solid state laser (Millenia, Spectra Physics) was used as a source of excitation. The Ti:sapphire output, tuned to 830 nm, was frequency doubled by second harmonic generation (SHG) in a β-barium borate (β-BBO) crystal to obtain the 415-nm light, and was coupled into a single mode fiber for delivery into the confocal scan head. A long-pass filter, 585 LP (585 nm), and an additional band pass filter with transmission at 680±15 nm (Chroma 680/30) were used as emission filters for fluorescence imaging. [0068] Figures IA and IB show the relative optical densities (read at 663 nm, the long-wavelength absorbance peak for IP) of the 'filtrate' and 'retentate' fractions, as well as the non-filtered 'original' samples, for NY-362 through NY-365. The non-silylated photosensitizer 3-iodobenzyl-pyro, or EP (compound I, Scheme 1), is used as the control, both dissolved in Tween-80 micelles as well as encaphotosensitizerulated in ORMOSIL nanoparticles.
[0069] From the Figure IA, it is evident that while NY-362 does not form any nanoparticles and most of the Iphotosensitizer is associated with the Tween-80 micelles which are collected in the filtrate, almost 80-90% of the Iphotosensitizer is associated with the nanoparticles in NY-363 through NY-365, which can be collected as the 'retentate'. Inability of pure Iphotosensitizer to form the nanoparticles is evidently associated with the steric hindrances due to bulky EP moieties, and nanoparticles are formed by combining both Iphotosensitizer and VTES precursors. A formation of the rigid, spherical and monodisperse nanoparticles with size about 20 nm for NY-363 is shown by TEM (Fig.l,B). It is worth noting that while TEM of NY-362 showed no formation of nanoparticles, thus confirming inability of Iphotosensitizer alone to form nanoparticles, NY-364 and NY-365 both formed the same-sized nanoparticles as NY-363 (data not shown), showing that the size of the nanoparticles is unaffected by the amount of the precursor used.
[0070] In order to confirm that EP is conjugated with the nanoparticles, and not merely physically associated, we have run both IP-conjugated and EP- encaphotosensitizerulated nanoparticles, as well as EP/micelles on silica-thin layer chromatography (Silica-TLC) plates in organic media ((Rf. ~0.5 in 10% Methanol/Dichloromethane). It can be seen that while the EP encaphotosensitizerulated in the nanoparticles (Lane 2) runs similar to EP in Tween-80 micelles (Lane 3) in the direction of the solvent front, the IP conjugated with the nanoparticles (NY-363) remains at the bottom, with
the nanoparticles (Lane 1). This means that organic media is not able to wash away the IP molecules from the NY-363, indicating irreversible linkage. We obtained similar data for NY-364 and NY-365 (data not shown). In sharp contrast, encaphotosensitizerulated IP molecules can be easily extracted from the nanoparticles by organic solvents. [0071] Photophysical properties. Absorption and fluorescence of the IP covalently incorporated into nanoparticle matrix are similar to that of encaphotosensitizerulated in the Tween-80 micelles (Figures 3A and 3B). Whereas samples of NY-363, NY-364, NY-365 have almost identical absorption and fluorescence spectra, while NY-362 (non-spin-filtered) shows little decrease in the fluorescence intensity. This correlates with little broadening of long-wave absorption band and can originate from the interaction of the Iphotosensitizer chromohores in tween-80 micelles (self-aggregation).
[0072] Aggregation of the photosensitizer chromophores is usually manifested both in decrease of fluorescence intensity and singlet oxygen generation.11' 12 Figure 4A presents emission spectra of singlet oxygen sensitized by samples of suspensions with absorbance and fluorescence shown in Figure 2. To distinguish singlet oxygen phosphorescence, which is known to have extremely low yield in water,13 we have used methanol solution of Rose Bengal as a standard for obtaining singlet oxygen phosphorescence. As seen in Figure 4A, IP chromophores incorporated within nanoparticles are capable of generating singlet oxygen with yield comparable to that of 1O2 generated by Tween-80 micelles. Intensity of the singlet oxygen emission sensitized in all suspensions of nanoparticles / micelles correlates with fluorescence intensity (Figure 3B). Intensity of 1O2 emission as well as fluorescence intensity that was almost identical for NY-363, NY-364, NY-365. IP/Tween-80 micellar suspension shows slightly higher fluorescence and 1O2 emission intensities, whereas intensity for NY-362 (non-spin-filtered) is lower. [0073] Correlation of the fluorescence and 1O2 emission intensities confirms aggregation affecting singlet oxygen generation. It is worth noting that the amount of singlet oxygen generated by photosensitizer (EP) in surfactant (Tween-80) micelles does depend on the relative amount of surfactant, which protects hydrophobic photosensitizer molecules from aggregation. Absence of difference in absorption/fluorescence/singlet oxygen generation for the samples NY-363, NY-364, NY-365 shows that aggregation effect does not manifest itself in the micelle-free Iphotosensitizer/VTES nanoparticles and relative content of Iphotosensitizer within nanoparticles can be further increased to obtain higher 1O2 generation for more efficient PDT action. Singlet oxygen phosphorescence steady-state spectroscopy well characterizes singlet oxygen generation in a homogeneous medium. However, in a
heterogeneous medium (i.e. water dispersion of a nanoparticles with embedded photosensitizer), question arises how observed 1O2 phosphorescence intensity will correlate with a phototoxic efficiency of the generated 1O2, because it could be, in principle, mostly deactivated within nanoparticles due to the limited lifetime of 1O2. [0074] Singlet oxygen mediated bleaching of the disodium salt of 9,10- anthracenedipropionic acid (ADPA) was used as an independent method for investigating the functional effect of the generated 1O2 outside nanoparticles. Here, we have added ADPA to the suspension of nanoparticles and recorded the time-dependent reduction of the ADPA absorption peak at 400 nm upon continuous irradiation with laser light (514 nm). The slope of the curves obtained is an indication of the functional efficiency of generated singlet oxygen (more the slope, more is the efficiency).14
[0075] As seen in Figure 4B, results on singlet oxygen production, which were obtained with method of ADPA bleaching, showed remarkable similarity to those obtained by singlet oxygen phosphorescence spectroscopy (Figure 4B), following the same trend: IP/Tween-80 micellar suspension demonstrated higher 1O2 generation then NY-363, NY-364, NY-365, whereas intensitiy for NY-362 is lower. This means that singlet oxygen generated within nanoparticles is mostly deactivated outside nanoparticles, causing bleaching of ADPA. In this case, lifetime of the singlet oxygen generated within nanoparticles should be determined by the water environment and be around 4μs.13 [0076] Figure 5 is a graph showing decays of emission at 1270 nm. Signal obtained for the suspension of neat ORMOSIL nanoparticles (100% of VTES) was used as Instrument Response Function (IRF). Rose Bengal (RB) in methanol was used as a reference standard producing singlet oxygen. Figure 5 shows decays of the emission from
Iphotosensitizer/VTES nanoparticle and IP Tween-80 suspensions at 1270 nm. Along with fast decay component coming from the scattered excitation light, one can see slow component with characteristic lifetime in microsecond range, which is definitely from singlet oxygen phosphorescence decay. Decays of 1O2 emission sensitized by
Iphotosensitizer/VTES are very close to that sensitized by IP/Tween-80 micellar suspension and have average lifetime (τ) in the range of 4.5-5 μs. In Figure 5, decay of 1O2 emisssion sensitized by RB in methanol is also shown, demonstrating monoexponential fitting with τ wlOμs, which is characteristic lifetime for 1O2 in methanol.13 Rise time of the 1O2 emission sensitized by the nanoparticle / micellar suspensions is noticeably higher then for RB molecular solution, including time of diffusion of the molecular oxygen to the incorporated
photosensitizer chromophores. However, since decay time is close enough to that for 1O2 in water and action of the singlet oxygen was demonstrated in the ADPA bleaching experiment, we consider that EP chromophores within Iphotosensitizer/VTES nanoparticles retain their functionality as photosensitizer for PDT. [0077] Cellular uptake. Since nanoparticles are capable of singlet oxygen production, which is indispensable condition for successful application in PDT, we have tested cellular uptake of the nanoparticles in vitro. Figure 6 presents confocal images of Colon-26 cells treated overnight with nanoparticles of NY-363, NY-364, NY-365 formulation. As one can see, there is significant uptake of the nanoparticles for all formulations. Since imaging conditions were maintained same (in particular, confocal pinhole and aperture for fluorescence imaging), on can see that fluorescence intensity for NY-364 is higher than for NY-365 and is the highest for NY-363, correspondingly to the amount of the IP moieties (N) within nanoparticles (NNY363> NNY364 > NNY365 ). This is understandable, assuming that the average amount of the nanoparticles uptaken by cells is similar for all formulations. Figure 6 is a plurality of micrographs showing cellular uptake Colon-26 cells treated overnight with NY-363 (A), NY-364 (B), NY-365 (C). Transmission (above) and fluorescence (below) channels are shown. Confocal pinhole and PMT gain remained same during imaging. [0078] A structural representation of a nanoparticle in accordance with the invnetion is shown in Figure 7. As shown in Figure 7, a nonoparticle 10 is shown having linked Ri and R2 groups where Ri = labeled photosensitizer (IP) or unlabeled photosensitizer (P), cyanine dye, SPECT, or PET, MR or fluorescent imaging agent and R2 is -OH, -COOH, -NH, cyanine dye, SPECT, PET, MR or fluorescent imaging agent, linked targeting agent RGD, F3 peptide, carbohydrate or folic acid or labeled photosensitizer (EP) or unlabeled photosensitizer (P) where a plurality of R2 groups, R2 groups or mixtures thereof are photosensitizer and/or labeled photosensitizer where Rj is at least 80 percent embedded within the nanoparticle and R3 is at least 40 percent exposed at the surface of the nanoparticle.
[0079] As described above, synthesis of highly monodispersed aqueous dispersion of the ORMOSIL nanoparticles with covalently incorporated photosensitizer molecule is shown. Photophysical characterization has shown that the spectroscopic and functional (generation of cytotoxic singlet oxygen) properties of the photosensitizer moieties are preserved in their 'nanoconjugated' state. These nanoparticles are also avidly uptaken by tumor cells in culture, thus demonstrating the potential of these nanoparticles for PDT. In addition, it is also possible to chemically replace the iodine atom of the iodinated photosensitizer (EP) with a
radiolabeled Iodine atom (e.g. 1-124, 125 etc), thus converting these nanoparticles as contrast agents for PET/SPECT imaging, while preserving their therapeutic functionality. [0080] Chemical modification of existing photosensitizers, to provide water solubility is described as is chemical conjugation of targeting group photosensitizer to existing photosensitizers, to increase the accumulation selectivity to diseased tissues.
[0081] Similarly, in accordance with the invention highly stable aqueous formulations of organically modified silica (ORMOSIL) nanoparticles encapsulating the hydrophobic photosensitizer HPPH [2-devinyl-2-(l-hexyloxyethyl)pyropheophorbide] have been made. This encaphotosensitizerulated photosensitizer is also able to generate singlet oxygen upon photoactivation owing to the free diffusion of molecular oxygen across the ORMOSIL matrix (Roy, I. et al., Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 2003, 125, (26), 7860-5). Again, because of mesoporosity of the ORMOSIL matrix, encaphotosensitizerulation of photosensitizer does not exclude the photosensitizer release, at least partially, during systemic circulation.
[0082] Again, in order to circumvent this problem, in accordance with the present invention, a modified formulation of the nanoparticles is provided with the photosensitizer molecule being covalently linked, instead of just being physically encaphotosensitizerulated. [0083] In accordance with the invention, nanoparticle conjugated (covalently linked) photosensitizers have been demonstrated having simple preparation that eliminate the possibility of premature release of the photosensitizer to unwanted sites in vivo. Additionally, the invention permits ease of active targeting by attaching targeting grouphotosensitizer on the particle surface [0084] As an additional option, the composite contains a covalently linked radioactive atoms for PET/SPECT imaging or magnetic resonance imaging contrast agents (i.e gadolinium).
Claims
1. A nano particle having the structural formula:
where the ring represents a silicone polymer matrix, where R4 is (Ri)n-R2 -(Rs)n where Ri is a labeled photosensitizer (IP) or unlabeled photosensitizer (P), cyanine dye, SPECT imaging agent, PET imaging agent, MR imaging agent or fluorescent imaging agent at least partially available at a surface of the silicone polymer matrix; R2 is -O-, -COO-, -NR5 or -NH- connected to the silicone polymer matrix directly or through an intermediate group, n is 0 or 1; provided that at least one n is 1 and R3 is cyanine dye, SPECT, PET, MR or fluorescent imaging agent, linked targeting agent RGD, F3 peptide, carbohydrate or folic acid or labeled photosensitizer (IP) or unlabeled photosensitizer (P) embedded in the silicone polymer matrix, and R5 is lower alkyl of from 1 to 5 carbon atoms where a plurality of Ri groups, R3 groups or mixtures thereof are photosensitizer and/or labeled photosensitizer.
2. The nanoparticle of claim 1 where the intermediate group is subtituted or unsubstituted alkylene or phenylene.
3. The nanoparticle of claim 2 where the alkylene or phenylene is substituted with at least one hydroxy, carboxy, amino, sulfo, alkylester, alkylether, heterocyclo, or halo group.
4. The nanoparticle of claim 1 where at least one Ri or R3 group is a tetrapyrollic photosensitizer selected from the group consisting of porphyrins, chlorins, bacteriochlorins, benzochlorins, benzoporphyrins, pheophorbides including pyropheophorbides, and derivatives thereof.
5. The nanoparticle of claim 1 where at least one Ri or R3 group is selected from the group consisting of phthalocyanine, naphthanocyanine and derivatives thereof.
6. The nanoparticle of claim 1 where at least one of Ri and R3 is a radionuclide MR or fluorescencent imaging agent.
7. A nanoparticle of claim 1 where a plurality of Ri groups are photosensitizers located at peripheral positions on the nanoparticle and a plurality of Ri groups are imaging agents located at peripheral positions on the nanoparticle.
8. A nanoparticle of claim 1 wherein it is provided with biotargeting molecules following suitable surface functionalization to obtain target-specific nanoparticles.
9. The nanoparticle of claim 8 wherein the biotargeting molecule is an antibody and the suitable surface functionalization is a ligand.
10. A nanoparticle of claim 1 further including at least one diagnostic agent.
11. A method for forming such nanoparticles includes the steps of : a) forming a uniform medium comprising from about 70 to about 80 weight percent of a lower alcohol selected from isopropanol, n-butanol, isobutanol and n-pentanol, from about 20 to about 30 weight percent of DMSO, from about 2 to about 3 percent water and from about 0.05 to about 0.15 percent of sufficient surfactant to maintain a dispersion; b) uniformly incorporating one or more silanes, as above described wherein the amount of silane or mixtures of silanes is about the maximum permitted for stability; c) adding sufficient reactive basic compound to form nanoparticles having reactive hydroxyl, amino, mercapto and/or carboxy groups exposed at their surface; d) dialyzing the nanoparticles through a membrane having a pore size of from about 0.1 to about 0.3 μM; e) during step b) or prior to step d), reacting a photosensitizer with a reactive group on the surface of the nanoparticles.
12. The method of claim 11 where the surfactant is a polyoxyethylene sorbitan monooleate or sodium dioctyl sulfosucinate.
13. The method of claim 11 where the silane is vinyltrimethoxysilane, vinyltriethoxysilane, vinylytriacetosilane, γ-glycidoxypropyltrimethoxysilane, γ- methacryloxypropyltrimethoxysilane, γ-aminopropyltrimethoxysilane, γ- aminopropyltriethoxysilane, γ-mercaptopropyltrimethoxy-silane, y-3,4- epoxycyclohexyltrimethoxysilane, phenyltrimethoxysilane or mixtures thereof.
14. The method of claim 1 where the silane is vinyltriethoxysilane or phenyltrimethoxysilane and the basic compound is ammonia or 3-aminopropylethoxysilane.
15. The method of claim 11 where the photosensitizer is a tetrapyrrole-based photosensitizing compound selected from the group consisting of porphyrins, chlorins, bacteriochlorins and derivatives thereof.
16. The method of claim 15 where the photosensitizer is selected from the group consisting of benzochlorins, benzoporphyrins, pheophorbides, pyropheophorbides, phthalocyanines, naphthanocyanines and derivative thereof.
17. The method of calim 11 where a targeting agent selected from the group consisting of monoclonal antibodies, integrin-antagonists and carbohydrates having high affinity for target tissue is reacted with at least one of the surface reactive groups.
18. A method for treating hyperproliferative tissue in an organism by infusing a compound according to claim 1 into the organism and exposing the hyperproliferative tissue to light at an activating wavelength of the photosensitizer.
19. A method for imaging hyperproliferative tissue in an organism by infusing a compound according to claim 1 having an incorporated imaging agent into the organism and imaging using the incorporated imaging agent.
20. The nanoparticle of claim 1 where the photosensitizer has the structure:
and its complexes with X where:
R, is -CH=CH2, -CH2CH3, -CHO, -COOH, or
H3C\ /R9
where R9 = -ORi0 where Rio is lower alkyl of 1 through 8 carbon atoms, -(CH2-O)nCH3, -(CH2)2CO2CH3, -(CH2)2CONHphenyleneCH2DTPA,
-CH2CH2CONH(CONHphenyleneCH2DTPA)2 , -CH2Rn or
R fluorescent dye moiety; R2, R2a, R3, R3a, R4, R5, Rsa, R7, and R7a are independently hydrogen, lower alkyl or substituted lower alkyl or two R2, R23, R3, R3a, R5, Rsa, R7, and R73 groups on adjacent carbon atoms may be taken together to form a covalent bond or two R2, R2a, R3j R3a, R5, Rsa, R7, and R7a groups on the same carbon atom may form a double bond to a divalent pendant group; R2 and R3 may together form a 5 or 6 membered heterocyclic ring containing oxygen, nitrogen or sulfur; R$ is -CH2-, -NRn- or a covalent bond; Rg is -(CH2)2CO2CH3, -(CH2)2CONHphenyleneCH2DTPA, -CH2CH2CONH(CONHphenyleneCH2DTPA)2, -CH2Rn or QJC where
R 1 i "N" R i 1
Rn is -CH2CONH-RGD-Phe-Lys, -CH2NHCO-RGD-PhC-LyS, a fluorescent dye moiety, or -CH2CONHCH2CH2SO2NHCH(CO2)CH2NHCOPhenylOCH2CH2NHcycloCNH(CH2)3N; and polynuclide complexes thereof; provided that the compound contains at least one integrin antagonist selected from the group consisting of -CH2CONH-RGD-Phe-Lys, -CH2NHCO-
RGD-Phe-Lys and
-CH2CONHCH2CH2SO2NHCH(CO2)CH2NHCOPhenylOCH2CH2NHcycloCNH(CH2)3N, where X is a metal selected from the group consisting of Zn, In, Ga, Al, or Cu or a radioisotope labeled moiety wherein the radioisotope is selected from the group consisting of 11C, 18F, 64Cu,
124I5 99Tc, 111In and GdIII .
21. The nanoparticle of claim 1 where the photosensitizer is a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and an element X where X is a metal containing moiety selected from the group consisting of Zn, In, Ga, Al, or Cu or a radioisotope labeled moiety wherein the radioisotope is selected from the group consisting of 11C, 18F, 64Cu, 124I, 99Tc,
111In and GdIII.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99380707P | 2007-09-14 | 2007-09-14 | |
US60/993,807 | 2007-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009038659A2 true WO2009038659A2 (en) | 2009-03-26 |
WO2009038659A3 WO2009038659A3 (en) | 2009-09-03 |
Family
ID=40468678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/010608 WO2009038659A2 (en) | 2007-09-14 | 2008-09-11 | Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009038659A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2956109A1 (en) * | 2010-02-11 | 2011-08-12 | Commissariat Energie Atomique | PROCESS FOR THE STOBER PREPARATION OF SILICA PARTICLES CONTAINING A PHTHALOCYANINE DERIVATIVE, THE SAID PARTICLES AND USES THEREOF |
EP2186862A3 (en) * | 2008-10-31 | 2011-09-21 | Westfälische Wilhelms-Universität Münster | The manufacture and products thereof of photosensitizing nanomaterials and their use in photodynamic treatment |
US20120184495A1 (en) * | 2009-06-12 | 2012-07-19 | Amrita Vishwa Vidyapeetham University Kerala | Targeted nano-photomedicines for photodynamic therapy of cancer |
EP2484388A1 (en) * | 2011-02-05 | 2012-08-08 | MaRVis Technologies GmbH | Implantable or insertable MRI-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it |
EP2591056A1 (en) * | 2010-07-06 | 2013-05-15 | Health Research, INC. | Metallation enhancements in tumor-imaging and pdt therapy |
EP2692365A1 (en) * | 2012-08-03 | 2014-02-05 | MaRVis Medical GmbH | Implantable or insertable MRI-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it |
PT107125A (en) * | 2013-08-23 | 2015-02-23 | Inst Superior Tecnico | SUPERPARAMAGNETIC MULTIFUNCTIONAL NANOSYSTEM AS CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGE AND ITS PRODUCTION METHOD |
JPWO2013073243A1 (en) * | 2011-11-18 | 2015-04-02 | 株式会社Adeka | Novel compound and carrier carrying the novel compound |
US9119875B2 (en) | 2013-03-14 | 2015-09-01 | International Business Machines Corporation | Matrix incorporated fluorescent porous and non-porous silica particles for medical imaging |
WO2016094991A1 (en) * | 2014-12-16 | 2016-06-23 | Universidade Estadual De Campinas - Unicamp | Method for producing pegylated silica nanoparticles as carriers of hydrophobic pharmaceutical drugs, thus obtained nanoparticles and uses thereof |
CN110718966A (en) * | 2019-10-25 | 2020-01-21 | 云南电网有限责任公司信息中心 | Data acquisition and management method for power equipment |
US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
CN114010598A (en) * | 2021-07-22 | 2022-02-08 | 中国药科大学 | Acid-responsive nanomicelles based on the Cherenkov effect and their preparation methods and applications |
CN115364211A (en) * | 2022-08-02 | 2022-11-22 | 北京大学 | Ultra-small phthalocyanine conjugated mesoporous silica nano particle and application thereof as sound-sensitive agent |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648485A (en) * | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
US20030157021A1 (en) * | 1995-02-02 | 2003-08-21 | Jo Klaveness | Light imaging contrast agents |
US20040180096A1 (en) * | 2003-01-24 | 2004-09-16 | Paras Prasad | Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same |
-
2008
- 2008-09-11 WO PCT/US2008/010608 patent/WO2009038659A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648485A (en) * | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
US20030157021A1 (en) * | 1995-02-02 | 2003-08-21 | Jo Klaveness | Light imaging contrast agents |
US20040180096A1 (en) * | 2003-01-24 | 2004-09-16 | Paras Prasad | Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2186862A3 (en) * | 2008-10-31 | 2011-09-21 | Westfälische Wilhelms-Universität Münster | The manufacture and products thereof of photosensitizing nanomaterials and their use in photodynamic treatment |
US8193343B2 (en) | 2008-10-31 | 2012-06-05 | Westfalische Wilhelms-Universitat Munster | Manufacture and products thereof of photosensitizing nanomaterials and their use in photodynamic treatment |
US20120184495A1 (en) * | 2009-06-12 | 2012-07-19 | Amrita Vishwa Vidyapeetham University Kerala | Targeted nano-photomedicines for photodynamic therapy of cancer |
WO2011098504A1 (en) * | 2010-02-11 | 2011-08-18 | Commissariat à l'énergie atomique et aux énergies alternatives | Stöber method for preparing silica particles containing a phthalocyanine derivative, said particles and the uses thereof |
FR2956109A1 (en) * | 2010-02-11 | 2011-08-12 | Commissariat Energie Atomique | PROCESS FOR THE STOBER PREPARATION OF SILICA PARTICLES CONTAINING A PHTHALOCYANINE DERIVATIVE, THE SAID PARTICLES AND USES THEREOF |
US9155791B2 (en) | 2010-07-06 | 2015-10-13 | Health Research, Inc. | Metallation enhancements in tumor-imaging and PDT therapy |
EP2591056A1 (en) * | 2010-07-06 | 2013-05-15 | Health Research, INC. | Metallation enhancements in tumor-imaging and pdt therapy |
EP2591056A4 (en) * | 2010-07-06 | 2013-09-11 | Health Research Inc | METALLURGIC GAINS IN TUMOR IMAGING AND PDT THERAPY |
EP2484388A1 (en) * | 2011-02-05 | 2012-08-08 | MaRVis Technologies GmbH | Implantable or insertable MRI-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it |
WO2012104102A1 (en) * | 2011-02-05 | 2012-08-09 | Marvis Technologies Gmbh | Implantable or insertable mri-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it |
CN103491987A (en) * | 2011-02-05 | 2014-01-01 | 马维斯医疗股份有限公司 | Implantable or insertable mri-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it |
US9530571B2 (en) | 2011-11-18 | 2016-12-27 | Adeka Corporation | Compound and support material supporting this novel compound |
JPWO2013073243A1 (en) * | 2011-11-18 | 2015-04-02 | 株式会社Adeka | Novel compound and carrier carrying the novel compound |
US10814044B2 (en) | 2012-08-03 | 2020-10-27 | Marvis Interventional Gmbh | Implantable or insertable MRI-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it |
WO2014019705A1 (en) | 2012-08-03 | 2014-02-06 | Marvis Medical Gmbh | Implantable or insertable mri-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it |
EP2692365A1 (en) * | 2012-08-03 | 2014-02-05 | MaRVis Medical GmbH | Implantable or insertable MRI-detectable medical device having a coating comprising paramagnetic ions and a process for preparing it |
US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
US9119875B2 (en) | 2013-03-14 | 2015-09-01 | International Business Machines Corporation | Matrix incorporated fluorescent porous and non-porous silica particles for medical imaging |
US9549996B2 (en) | 2013-03-14 | 2017-01-24 | International Business Machines Corporation | Matrix incorporated fluorescent porous and non-porous silica particles for medical imaging |
WO2015026252A1 (en) | 2013-08-23 | 2015-02-26 | Instituto Superior Tecnico | Multifunctional superparamagnetic nanosystem as contrast agent for magnetic resonance imaging and its production method |
PT107125A (en) * | 2013-08-23 | 2015-02-23 | Inst Superior Tecnico | SUPERPARAMAGNETIC MULTIFUNCTIONAL NANOSYSTEM AS CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGE AND ITS PRODUCTION METHOD |
WO2016094991A1 (en) * | 2014-12-16 | 2016-06-23 | Universidade Estadual De Campinas - Unicamp | Method for producing pegylated silica nanoparticles as carriers of hydrophobic pharmaceutical drugs, thus obtained nanoparticles and uses thereof |
CN110718966A (en) * | 2019-10-25 | 2020-01-21 | 云南电网有限责任公司信息中心 | Data acquisition and management method for power equipment |
CN114010598A (en) * | 2021-07-22 | 2022-02-08 | 中国药科大学 | Acid-responsive nanomicelles based on the Cherenkov effect and their preparation methods and applications |
CN115364211A (en) * | 2022-08-02 | 2022-11-22 | 北京大学 | Ultra-small phthalocyanine conjugated mesoporous silica nano particle and application thereof as sound-sensitive agent |
CN115364211B (en) * | 2022-08-02 | 2023-12-22 | 北京大学 | Ultra-small phthalocyanine conjugated mesoporous silica nanoparticle and application thereof as sound sensitizer |
Also Published As
Publication number | Publication date |
---|---|
WO2009038659A3 (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009038659A2 (en) | Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy | |
US20220296714A1 (en) | Targeted nano-photomedicines for photodynamic therapy of cancer | |
Ohulchanskyy et al. | Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer | |
Couleaud et al. | Silica-based nanoparticles for photodynamic therapy applications | |
Guan et al. | Photodynamic therapy based on nanoscale metal–organic frameworks: from material design to cancer nanotherapeutics | |
Itoo et al. | Nanotherapeutic intervention in photodynamic therapy for cancer | |
Siwawannapong et al. | Ultra-small pyropheophorbide-a nanodots for near-infrared fluorescence/photoacoustic imaging-guided photodynamic therapy | |
Lucky et al. | Nanoparticles in photodynamic therapy | |
US20110288234A1 (en) | Silica nanoparticles postloaded with photosensitizers for drug delivery in photodynamic therapy | |
Li et al. | Highly water-soluble and tumor-targeted photosensitizers for photodynamic therapy | |
Pantiushenko et al. | Development of bacteriochlorophyll a-based near-infrared photosensitizers conjugated to gold nanoparticles for photodynamic therapy of cancer | |
CN110996963A (en) | Conjugates of active pharmaceutical ingredients | |
US7230088B2 (en) | Compounds for dual photodiagnosis and therapy | |
Thanasekaran et al. | Lipid-wrapped upconversion nanoconstruct/photosensitizer complex for near-infrared light-mediated photodynamic therapy | |
Lim et al. | Iodinated photosensitizing chitosan: Self-assembly into tumor-homing nanoparticles with enhanced singlet oxygen generation | |
Shinn et al. | Recent progress in development and applications of second near‐infrared (NIR-II) nanoprobes | |
US20200345846A1 (en) | Corrole compositions | |
Laxman et al. | BF2-oxasmaragdyrin nanoparticles: a non-toxic, photostable, enhanced non-radiative decay-assisted efficient photothermal cancer theragnostic agent | |
Silindir‐Gunay et al. | Near‐infrared imaging of diseases: A nanocarrier approach | |
Del Valle et al. | Recent advances in near infrared upconverting nanomaterials for targeted photodynamic therapy of cancer | |
Alizadeh Nobari et al. | Emerging trends in quantum dot-based photosensitizers for enhanced photodynamic therapy in cancer treatment | |
US10568963B2 (en) | Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles | |
Liu et al. | New generation of photosensitizers based on inorganic nanomaterials | |
Galli et al. | SPIO@ SiO 2–Re@ PEG nanoparticles as magneto-optical dual probes and sensitizers for photodynamic therapy | |
Shabbirahmed et al. | Recent Advancements in Nanomaterials for Photodynamic Therapy of Cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08832507 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08832507 Country of ref document: EP Kind code of ref document: A2 |